Company Overview
Mechanobiologics, Inc. develops innovative low-frequency ultrasound (LFU) devices for both medical and wellness applications. Our proprietary technology rejuvenates aging cells and tissues by modulating mechanobiological pathways that regulate senescence and inflammation.
In laboratory studies, LFU treatment significantly extends the lifespan of cultured cells and delays or even reverses cellular senescence in vitro. Preclinical and early clinical research supports a wide range of potential medical applications, including:
-
Osteoarthritis: Clinical trials suggest improved joint function and reduced pain
-
Infection Risk: LFU stimulates immune responses in animal models
-
Cognitive Decline: Early results in Alzheimer's disease models show promise in slowing or reversing degeneration
-
Metabolic Inflammation: Animal studies show reduced inflammation associated with glucose intolerance and insulin resistance
In the wellness space, our spa-based systems are designed to support healthy aging by enhancing skin thickness, improving elasticity, and promoting overall well-being.
Back row: Lisheng Xu, Linda Kenney, Shuhan Liu, Dasvit Shetty, Mrinal Shah, Moirangthem Kiran Singh,
Front row: Yong Hwee Foo, Priscilla Liu, Parisa Zangoui, Yuki Yamanaka
Our Mission
To extend human healthspan by restoring the body’s innate regenerative capacity through the power of mechanicobiology.
Who We Are
Mechanobiologics, Inc. is a longevity biotechnology company developing non-invasive, low-frequency ultrasound therapies that reverse cellular aging. We build on decades of research by our founder, the late Michael P. Sheetz, whose work opened an entirely new frontier in regenerative medicine.